SitemapImprintDatenschutzerklärungdeutschenglish
MHH Logo

KIRA

 

KIRA

German Collaborative Asthma Cohort

 

 

Bronchial asthma is one of the most common chronic lung diseases in childhood and adolescence. In the majority of patients who suffer from asthma, the first symptoms already occur in early childhood. However, only a minority of patients who show in the first 2-3 years of life, which is typical of asthma and wheezing gasp, develop an allergic asthma at school age. The most common asthma phenotype of school age is associated with atopic sensitization to seasonal and perennial allergens, but again other children also suffer for years to non-allergic asthma. In adolescence the symptoms of some asthma patients become better, but in a substantial proportion of these patients, however, they return in adulthood.

In another group of patients the symptoms in adolescence are not stopping there, but evolve continuously to asthma in adulthood and associated pathological changes in the respiratory tract. These patients have a high risk to develop a severe form or a difficult to treated form of asthma. At this particularly severe form affects approximately 5-10% of asthma patients, however, the cost of their treatment makes a disproportionate share of health expenditure for this disease out.

The clinical study "Children and Asthma" (KIRA) aims to cover all pediatric asthma patients from the large pediatric, pulmonary clinics and of partnership, physicians over a period of three years. A selected number of patients with existing or new-onset asthma in preschool and adolescence should be characterized with respect to their immunological, genetic and microbial phenotype to in order to establish a well-characterized cohort and specifically watch the progression of the disease of the participants can.

With the project "German Collaborative Asthma cohort" is intended to show that specific Asthma phänotypes may be based on algorithms of certain clinical features, genetics or other, the biomarkers underlying mechanisms identified.

 

Patients:

  • circa 500 patients (2017)
    • 100 patients/year

      Samples:

      • blood
      • PAXgne
      • plasma
      • sera
      • swabs
      • cells


      Partner Site Manager:

      Prof. Dr. Gesine Hansen

      Cooperating partners in KIRA/DZL:

      Airway Research Center North (ARCN), Biomedical Research in Endstage And ObsTructive Lung Disease Hannover (BREATH), Comprehensive Pneumology Center (CPC) Munich, Universities of Giessen and Marburg Lung Center (UGMLC)

      KIRA is a study of the German Center of Lung Research (DZL).

       

      Link:

      http://www.breath-hannover.de/index.php?id=40